MainboardGMP
LIVE
LIVE GMP
MakeMyTrip (India) Ltd₹0·Sagar Defence Engineering Ltd₹0·Encube Ethicals Ltd₹0·Arjun Jewellers Ltd₹0·Atomberg Technologies Ltd₹0·GNI Infrastructure Ltd₹0·Punjab Carbonic Ltd₹0·Ratnadeep Retail Ltd.₹0·IFL Finance Ltd.₹0·J Pan Tubular Components Ltd₹0·MakeMyTrip (India) Ltd₹0·Sagar Defence Engineering Ltd₹0·Encube Ethicals Ltd₹0·Arjun Jewellers Ltd₹0·Atomberg Technologies Ltd₹0·GNI Infrastructure Ltd₹0·Punjab Carbonic Ltd₹0·Ratnadeep Retail Ltd.₹0·IFL Finance Ltd.₹0·J Pan Tubular Components Ltd₹0·
Home › IPOs › Bio Medica Laboratories Ltd › Issue Details
BI
Bio Medica Laboratories Ltd
CLOSED BSE SME Bookbuilding IPO Fresh capital cum OFS Bio Medica Laboratories IPO GMP
GREY MARKET PREMIUM
₹ + 2
+1% expected return
EST. LISTING PRICE
₹141
Issue Price: ₹ 139
Issue Price
₹139
Face Value
₹10
Lot Size
1,000 shares
Open Date
21 May 2026
Close Date
25 May 2026
Allotment
26 May 2026
Listing Date
29 May 2026
Exchange
BSE SME

Bio Medica Laboratories IPO Details: Price, Dates & Financials

The Bio Medica Laboratories IPO pre-issue shareholding stands at 9,180,001 shares. The Bio Medica Laboratories IPO post-issue shareholding is 12,575,001 shares. This means the Bio Medica Laboratories IPO fresh issue adds 3,395,000 new shares. The Bio Medica Laboratories IPO issue price is ₹139 per share.

Issue Details
Total Shares Offered
3,583,000
Reserved for Market Maker
Up to ₹3 Cr
Net Offer to Public
Up to ₹50 Cr
Pre-Issue Shareholding
9,180,001 shares
Post-Issue Shareholding
12,575,001 shares
Bio Medica Laboratories IPO Issue Details FAQs
Bio Medica Laboratories IPO offers 3,583,000 shares in total, of which Up to ₹50 Cr are the net offer to the public.
Shares reserved for the market maker in Bio Medica Laboratories IPO: Up to ₹3 Cr. The market maker provides two-way quotes after listing to keep the stock liquid.
Pre-issue shareholding: 9,180,001 shares. Post-issue shareholding: 12,575,001 shares.
Bio Medica Laboratories IPO is a Fresh capital cum OFS issue. Issue type: Bookbuilding IPO. Face value is ₹10.
The Red Herring Prospectus (RHP) of Bio Medica Laboratories IPO is available on the website of the lead manager and the stock exchange (BSE SME) — see the lead manager links on the main page.
The DRHP is the initial offer document filed for regulatory review, while the RHP includes updated disclosures, final issue details, and the price band (when announced). Comparing both documents helps investors identify changes in the Bio Medica Laboratories IPO's financial information, risks, and offer terms before investing in the Bio Medica Laboratories IPO. Reviewing both documents provides a clearer understanding of the Bio Medica Laboratories IPO before making an investment decision.
The DRHP and RHP of the Bio Medica Laboratories IPO disclose potential risks related to the company's business, financial performance, legal matters, and industry conditions. Reviewing these documents helps investors identify potential concerns about the Bio Medica Laboratories IPO, evaluate the Bio Medica Laboratories IPO's risk factors, and make a more informed decision before investing in the Bio Medica Laboratories IPO.

GMP and IPO data are unofficial and for information only — not investment advice. Read the full disclaimer.